Sath Shukla, Chief Financial Officer at Spero Therapeutics, Inc. (SPRO), sold 6,017 shares at $0.89 ($5K) on 2022-08-29, disclosed to the SEC on 2022-08-30.
Scheduled sale ($5k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| SPRO | SELL | 2024-08-06 | $43K | — | Filing → |
| SPRO | SELL | 2024-02-05 | $173K | — | Filing → |
| SPRO | SELL | 2023-08-30 | $8K | — | Filing → |